Changes in tumor sizes, CA-125, serum ceruloplasmin, and copper levels in 5 patients with platinum-resistant high-grade epithelial ovarian cancer who received.

Slides:

Advertisements

Similar presentations

“Taking Care of Tomorrows Patient Better than Today”… the Future is Now Set A1 – Title Slide David O’Malley, M.D.

Advertisements

James R. Rigas Comprehensive Thoracic Oncology Program

Signaling Pathways Produced By Combining DsRNA with Paclitaxal to treat Ovarian Cancer Switu Patel.

OCEANS: A Randomized, Double- Blinded, Placebo-Controlled Phase III Trial of Chemotherapy with or without Bevacizumab (BEV) in Patients with Platinum-

A, Effect of folate-FITC (500 nmol/kg, 5 days/week) and/or sunitinib (20 mg/kg daily) therapy on the growth of M109 tumors in Balb/c mice. A, Effect of.

Dose-escalation patient response.

An Introduction to DNA Damage Repair in Cancer: Beyond PARP

Activity Goals. Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?

PARP Inhibitors and Cancer: What Do You Need to Know?

Counseling Patients About Germline BRCA Mutations

High-throughput drug screen and validation to nominate patient-specific therapeutic options. High-throughput drug screen and validation to nominate patient-specific.

Prognostic significance of DDB2 in ovarian cancer.

Antitumor activity of BAY in patient-derived tumor models.

Identification of a MEK2 mutation in a melanoma sample resistant to dabrafenib/trametinib. Identification of a MEK2 mutation in a melanoma sample resistant.

Maintenance Therapy in Advanced Ovarian Cancer

Effects of SC144 on in vivo ovarian tumor.

Randomized phase III trial on Trabectedin (ET 743) vs clinician’s choice chemotherapy in recurrent ovarian, primary peritoneal or fallopian tube cancers.

What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

Objective response rate in patients with BRCA-mutated HER2-negative breast cancer treated with PARPi versus those treated with monochemotherapy (controls).

Computed tomographic images from a patient with BRAFL597S-mutant metastatic melanoma responding to therapy with the MEK inhibitor TAK-733. Computed tomographic.

A, IC50 dose–response curves of SYD985, T-DM1, and ADC isotype control in all USC cell lines tested in vitro (i.e., HER2 3+ cell lines, P =

Diagnostic plots of the TGI PKPD model fitted to the A677 TGI data.

The expression of SPINDLIN1 in cancer tissues.

Expression analysis of IGFBP-3 using human whole-genome microarray.

T-VISA is robust in ovarian cancer cell lines.

Effect of HA on hematopoietic recovery in tumor-bearing mice.

Expression profile of RSPO1 and 2 in gastric cancer.

NSG mice transplanted with human primary ALK-positive ALCL tumor grafts were administered either doxorubicin, 10 mg/kg i.v. or CEP orally, 100 mg/kg,

Protein expression profile in a dasatinib-resistant cell line.

Simulations to guide drug design strategies for anti–Bcl-2 therapy.

Reduced BAI1 expression is associated with breast cancer patient survival. Reduced BAI1 expression is associated with breast cancer patient survival. A,

Effect of nicotinamide and carbogen on 5-FU uptake (measured as SUV3

Correlation between serum visfatin concentrations and the clinical stage (A) and tumor size (B, C) of HCCs. A and B, the correlations were determined by.

Predictive value of the FGFR3 mutation assay increases with multiple consecutive FGFR3-positive urine samples. Predictive value of the FGFR3 mutation assay.

Immunohistochemical detection of nuclear and cytoplasmic YB-1 in osteosarcoma and synovial sarcoma. Immunohistochemical detection of nuclear and cytoplasmic.

Endothelial cells/microvasucles are increased in prostate cancer versus normal tissues. Endothelial cells/microvasucles are increased in prostate cancer.

High-throughput siRNA screening results and corresponding patient gene expression data for PP2A subunits. High-throughput siRNA screening results and corresponding.

Kaplan–Meier curves for PFS and OS (for patients treated with anti-PD-1/PD-L1 monotherapy). Kaplan–Meier curves for PFS and OS (for patients treated with.

Angiogenesis in tumors formed by cells varying in the expression of CXCR2. Angiogenesis in tumors formed by cells varying in the expression of CXCR2. A,

Curcumin enhances effects of bortezomib to inhibit angiogenesis in multiple myeloma tumor samples. Curcumin enhances effects of bortezomib to inhibit angiogenesis.

GA reduces the growth of Caki-1 tumor xenografts.

Modeling of EGFR exon 20 insertions using the 3-dimensional structure of the EGFR kinase domain predicts different interactions with the erlotinib-binding.

Positions of the EGFR exon 20 insertions identified over a 3-year period and comparison with the spectrum of EGFR exon 19 and HER2 insertion mutations.

Immunohistochemical analysis of dUTPase in human breast adenocarcinoma

Discovered and replicated positive correlation between miR-193b

Effect of miRNA mimic on platinum sensitivity.

Tumor and serum levels of murine IL-12.

Visualization of tumor vasculature using anti-CD31 immunohistochemistry. Visualization of tumor vasculature using anti-CD31 immunohistochemistry. Micrographs.

Xenograft regrowth studies.

GR CAFs modulate the EGFR-TKI response in cocultured tumor cells.

Simplified BRAF signaling network.

A, P causes G2-M arrest with apoptosis in asynchronous population of PC-3 when exposed to 1.5 and 5 μmol/L P for various time points. A, P

Kaplan-Meier survival analysis of p53 mutation in the overall breast tumor series. Kaplan-Meier survival analysis of p53 mutation in the overall breast.

Three-day biodistribution of 125I-labeled chTNT-3 administered at (A) 1, 2, or 3 days after pretreatment with VP-16 (30 mg/kg) in MAD109 bearing BALB/c.

Association between BRCA1 transcript level and cisplatin sensitivity, BRCA1 promoter methylation, and NtAI. Association between BRCA1 transcript level.

Ki-67 expression in M31- and H3-treated tumors (A) and respective Ki-67 labeling indices in the two groups of tumors (B). Ki-67 expression in M31- and.

SBC-5 miR-335+, but not SBC-5 miR-29a+, exhibited reduced IGF-IR expression. SBC-5 miR-335+, but not SBC-5 miR-29a+, exhibited reduced IGF-IR expression.

A, tumor growth studies in H1975 tumor–bearing mice.

CRA inhibits the growth of human tumor xenografts in vivo.

Immunohistochemical staining for FOXO3a of breast cancer tumor tissues

Antitumor activity. Antitumor activity. A, maximum change in target lesion size from baseline assessed according to RECIST 1.0 (n = 26). Six patients had.

A 63-year-old female with lung adenocarcinoma treated with nivolumab, who experienced pseudoprogression. A 63-year-old female with lung adenocarcinoma.

Molecular heterogeneity drives secondary resistance to anti-EGFR therapies in mCRC. Molecular heterogeneity drives secondary resistance to anti-EGFR therapies.

Representative patient responses to ulixertinib.

ROC analysis of MIC-1 and CA19-9.

Venn diagram showing the overlap of PD-L1 overexpression, MSI-NGS–high, and TML-high in all gastrointestinal tumors, with all three markers tested (N =

Detection of BRCA reversion mutations in pretreatment cfDNA and tumor biopsy. Detection of BRCA reversion mutations in pretreatment cfDNA and tumor biopsy.

Epithelial and stromal percentage clusterin staining in normal nonadjacent colonic tissue and matched tumor tissue in 202 patients with stage II colorectal.

E2F4 program is predictive of the efficacy of intravesical BCG immunotherapy in NMIBC. A, the survival curves of intravesical therapy-treated and untreated.

Presentation transcript:

Changes in tumor sizes, CA-125, serum ceruloplasmin, and copper levels in 5 patients with platinum-resistant high-grade epithelial ovarian cancer who received 2 cycles of therapy with trientine and carboplatin. Changes in tumor sizes, CA-125, serum ceruloplasmin, and copper levels in 5 patients with platinum-resistant high-grade epithelial ovarian cancer who received 2 cycles of therapy with trientine and carboplatin. All patients received carboplatin at AUC 6, except for patient 1 who received carboplatin at AUC 4. Patient 5 had a BRCA1 mutation. Siqing Fu et al. Mol Cancer Ther 2012;11:1221-1225 ©2012 by American Association for Cancer Research